title: HLA-B*5701 testing to predict abacavir hypersensitivity.
abstract: Abacavir is a nucleoside reverse transcriptase inhibitor used for combination antiretroviral therapy for treating human immunodeficiency virus (HIV) infection. An adverse effect from abacavir is a treatment-limiting hypersensitivity reaction, which can be severe and potentially life-threatening. Abacavir-induced hypersensitivity reaction has been associated with the presence of the major histocompatibility complex class I allele HLA-B*5701. A screening test for the HLA-B*5701 allele can assist clinicians to identify patients who are at risk of developing a hypersensitivity reaction to abacavir.
authors.affiliation: University of California, San Diego, Skaggs School of Pharmacy & Pharmaceutical Sciences and University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Ma
authors.forename: Kelly C
authors.initials: KC
authors.lastname: Lee
authors.forename: Grace M
authors.initials: GM
authors.lastname: Kuo